Aurobindo Pharma shares rise 2% after subsidiary CuraTeQ gets UK nod for Dyrupeg

Aurobindo Pharma shares rose 2.2% to an intraday high of Rs 1,119.90 on the BSE on Wednesday after its wholly-owned step-down subsidiary, CuraTeQ Biologics s.r.o., received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg, a biosimilar of pegylated filgrastim.

"CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Ltd, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Dyrupeg™, its pegylated filgrastim biosimilar version," according to a stock exchange filing.

This is CuraTeQ’s third biosimilar approval from the UK regulator, following the authorisations of Bevqolva in December 2024 and Zefylti in May 2025. Dyrupeg is used to reduce the risk of infection in cancer patients undergoing chemotherapy and had earlier received marketing approval from the European Commission in April 2025.


Also Read:Coforge among 10 high-conviction stock ideas that can rally up to 52%

Aurobindo Pharma Q4 earnings

For the March quarter, Aurobindo Pharma reported an 11% year-on-year rise in consolidated revenue to Rs 8,382.1 crore, broadly in line with Street expectations. The growth was mainly driven by a 13.5% YoY increase in US formulation sales and a 17.2% jump in European formulations.

Net profit for the quarter stood at Rs 902.8 crore, marginally lower than Rs 907.4 crore in the same quarter last year. EBITDA rose 7.1% YoY to Rs 1,792 crore, with an EBITDA margin of 21.38%, slightly down from the previous year.

Also Read: 11 Nifty mid & smallcap stocks that can rally 40-90% over the next 12 months

Aurobindo Pharma shares price target

According to Trendlyne, the average target price for Aurobindo Pharma shares is Rs 1,403, indicating a potential 27% upside from current levels. Among 27 analysts covering the stock, the consensus rating is 'Buy'.

On Tuesday, the stock closed 0.4% higher at Rs 1,104 on the BSE. While it has declined 18% year-to-date, it has more than doubled—rising 110%—over the past three years. The company’s current market capitalisation is around Rs 64,120 crore.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)